Laboratory of Immunoncology, Fundación Ciencia & Vida, Santiago, Chile.
Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile.
Methods Mol Biol. 2021;2197:225-239. doi: 10.1007/978-1-0716-0872-2_12.
DNA vaccines assisted by electroporation efficiently trigger antitumor cytotoxic CD8 T cell responses in preclinical cancer models and hold potential for human use. They can be easily engineered to express either tumor-associated self-antigens, which are broadly expressed among tumor patients but also in healthy tissue, or tumor-specific neoantigens, which are uniquely expressed in tumors and differ among patients. Recently, it has been demonstrated that DNA vaccination generates both circulating and tissue-resident compartments of CD8 T cells, which act concertedly against tumors. Here we describe the steps to obtain and test DNA vaccines against models of self-antigens and neoantigens in mice. It includes the evaluation of effector and memory CD8 T cell responses, as well as assessing the antitumor potential in vivo using transplantable syngeneic tumor models.
电穿孔辅助 DNA 疫苗可有效地在临床前癌症模型中引发抗肿瘤细胞毒性 CD8 T 细胞反应，并且具有用于人类的潜力。它们可以很容易地被设计为表达肿瘤相关的自身抗原，这些抗原在肿瘤患者中广泛表达，但也在健康组织中表达，或者表达肿瘤特异性的新抗原，这些新抗原仅在肿瘤中表达并且在患者之间存在差异。最近已经证明，DNA 疫苗可产生循环和组织驻留的 CD8 T 细胞区室，这些细胞协同作用以对抗肿瘤。在这里，我们描述了在小鼠中获得和测试针对自身抗原和新抗原模型的 DNA 疫苗的步骤。它包括评估效应器和记忆 CD8 T 细胞反应，以及使用可移植的同基因肿瘤模型在体内评估抗肿瘤潜力。
